162 related articles for article (PubMed ID: 35821497)
1. The efficacy and safety of cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: A comparative analysis of retrospective studies versus prospective studies.
Wang BC; Xiao BY; Kuang BH; Lin GH
Dermatol Ther; 2022 Sep; 35(9):e15715. PubMed ID: 35821497
[TBL] [Abstract][Full Text] [Related]
2. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
Migden MR; Khushalani NI; Chang ALS; Lewis KD; Schmults CD; Hernandez-Aya L; Meier F; Schadendorf D; Guminski A; Hauschild A; Wong DJ; Daniels GA; Berking C; Jankovic V; Stankevich E; Booth J; Li S; Weinreich DM; Yancopoulos GD; Lowy I; Fury MG; Rischin D
Lancet Oncol; 2020 Feb; 21(2):294-305. PubMed ID: 31952975
[TBL] [Abstract][Full Text] [Related]
3. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P
Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948
[TBL] [Abstract][Full Text] [Related]
4. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
Migden MR; Rischin D; Schmults CD; Guminski A; Hauschild A; Lewis KD; Chung CH; Hernandez-Aya L; Lim AM; Chang ALS; Rabinowits G; Thai AA; Dunn LA; Hughes BGM; Khushalani NI; Modi B; Schadendorf D; Gao B; Seebach F; Li S; Li J; Mathias M; Booth J; Mohan K; Stankevich E; Babiker HM; Brana I; Gil-Martin M; Homsi J; Johnson ML; Moreno V; Niu J; Owonikoko TK; Papadopoulos KP; Yancopoulos GD; Lowy I; Fury MG
N Engl J Med; 2018 Jul; 379(4):341-351. PubMed ID: 29863979
[TBL] [Abstract][Full Text] [Related]
5. Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center.
Ríos-Viñuela E; Álvarez P; Lavernia J; Serra-Guillén C; Requena C; Bernia E; Diago A; Llombart B; Sanmartín O
Actas Dermosifiliogr; 2022 Jun; 113(6):T610-T615. PubMed ID: 35525283
[TBL] [Abstract][Full Text] [Related]
6. Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center.
Ríos-Viñuela E; Álvarez P; Lavernia J; Serra-Guillén C; Requena C; Bernia E; Diago A; Llombart B; Sanmartín O
Actas Dermosifiliogr; 2022 Jun; 113(6):610-615. PubMed ID: 35431057
[TBL] [Abstract][Full Text] [Related]
7. Advanced cutaneous squamous cell carcinoma: Impact of age on the safety and efficacy of cemiplimab and the prognostic significance of blood biomarkers.
Ksienski D; Truong PT; Bone JN; Egli S; Clarkson M; Patterson T; Lesperance M; Lakkunarajah S
J Geriatr Oncol; 2024 Jun; 15(5):101789. PubMed ID: 38710153
[TBL] [Abstract][Full Text] [Related]
8. Cemiplimab in advanced cutaneous squamous cell carcinoma.
Naik PP
Dermatol Ther; 2021 Nov; 34(6):e15184. PubMed ID: 34716727
[TBL] [Abstract][Full Text] [Related]
9. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.
Rischin D; Khushalani NI; Schmults CD; Guminski A; Chang ALS; Lewis KD; Lim AM; Hernandez-Aya L; Hughes BGM; Schadendorf D; Hauschild A; Thai AA; Stankevich E; Booth J; Yoo SY; Li S; Chen Z; Okoye E; Chen CI; Mastey V; Sasane M; Lowy I; Fury MG; Migden MR
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34413166
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitors for Advanced Cutaneous Squamous Cell Carcinoma: A Systematic Review with Meta-Analysis.
Mehta NK; Li AR; Nguyen SA; Kaczmar JM; Neskey DM; Day TA
Target Oncol; 2021 Nov; 16(6):743-752. PubMed ID: 34677815
[TBL] [Abstract][Full Text] [Related]
11. [Locally advanced and metastatic cutaneous squamous cell carcinoma treated with cemiplimab].
Vanhakendover L; Lebas E; Libon F; Wauters O; Dezfoulian B; Marchal N; Rorive A; Piret P; Quatresooz P; Jacquemin D; Nikkels AF
Rev Med Liege; 2019 Jul; 74(7-8):436-440. PubMed ID: 31373461
[TBL] [Abstract][Full Text] [Related]
12. Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios.
Akhtar K; Sravanthi MV; D'Angelo J; Sivapiragasam A
J Investig Med High Impact Case Rep; 2022; 10():23247096221121408. PubMed ID: 36017984
[TBL] [Abstract][Full Text] [Related]
13. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel.
Lebas E; Marchal N; Rorive A; Nikkels AF
Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680
[TBL] [Abstract][Full Text] [Related]
14. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Stratigos AJ; Sekulic A; Peris K; Bechter O; Prey S; Kaatz M; Lewis KD; Basset-Seguin N; Chang ALS; Dalle S; Orland AF; Licitra L; Robert C; Ulrich C; Hauschild A; Migden MR; Dummer R; Li S; Yoo SY; Mohan K; Coates E; Jankovic V; Fiaschi N; Okoye E; Bassukas ID; Loquai C; De Giorgi V; Eroglu Z; Gutzmer R; Ulrich J; Puig S; Seebach F; Thurston G; Weinreich DM; Yancopoulos GD; Lowy I; Bowler T; Fury MG
Lancet Oncol; 2021 Jun; 22(6):848-857. PubMed ID: 34000246
[TBL] [Abstract][Full Text] [Related]
15. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
Villani A; Ocampo-Garza SS; Potestio L; Fabbrocini G; Ocampo-Candiani J; Ocampo-Garza J; Scalvenzi M
Expert Opin Drug Saf; 2022 Jan; 21(1):21-29. PubMed ID: 34644510
[TBL] [Abstract][Full Text] [Related]
16. Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case.
Ghidini A; Santangelo D; Vaccaro G; Chillura M; Petrelli F
Oral Oncol; 2022 May; 128():105847. PubMed ID: 35367788
[TBL] [Abstract][Full Text] [Related]
17. IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab.
Mallardo D; Simeone E; Festino L; Tuffanelli M; Vanella V; Trojaniello C; Vitale MG; Ottaviano M; Capone M; Madonna G; Sparano F; Cioli E; Scarpato L; Palla M; Di Trolio R; Meinardi P; Caracò C; Ferrara G; Muto P; Cavalcanti E; Ascierto PA
J Transl Med; 2023 Feb; 21(1):140. PubMed ID: 36823670
[TBL] [Abstract][Full Text] [Related]
18. Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives.
Mager L; Gardeen S; Carr DR; Shahwan KT
Clin Cosmet Investig Dermatol; 2023; 16():2135-2142. PubMed ID: 37581012
[TBL] [Abstract][Full Text] [Related]
19. Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma.
Valentin J; Gérard E; Ferte T; Prey S; Dousset L; Dutriaux C; Beylot-Barry M; Pham-Ledard A
J Geriatr Oncol; 2021 Sep; 12(7):1110-1113. PubMed ID: 33736973
[TBL] [Abstract][Full Text] [Related]
20. Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Konidaris G; Paul E; Kuznik A; Keeping S; Chen CI; Sasane M; Xu Y; Atsou K; Ayers D; Ruiz ES; Khushalani NI; Cope S
Value Health; 2021 Mar; 24(3):377-387. PubMed ID: 33641772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
